AT7519是CDK抑制剂,对CDK1,2,4,6和9的IC50为10-210 nM,对CDK3的抑制性较低,而对CDK7则几乎无抑制性。
AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. Phase 2.
浓度 10 mM, 0.25-4 μM
15 mg/kg/day 腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Squires MS, et al. Mol Cancer Ther, 2009, 8(2), 324-332.
[2] E X Chen,et al. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br J Cancer. 2014 Dec 9; 111(12): 2262–2267. Published online 2014 Nov 13. doi: 10.1038/bjc.2014.565.
[3] David A Dorward,et al. The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome. Thorax. 2017 Feb; 72(2): 182–185. Published online 2016 Oct 24. doi: 10.1136/thoraxjnl-2016-209229.
分子式 C16H17Cl2N5O2 |
分子量 382.24 |
CAS号 844442-38-2 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 10 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01183949 | Multiple Myeloma | Drug: AT7519M|Drug: Bortezomib | Astex Pharmaceuticals|Multiple Myeloma Research Consortium | Phase 1|Phase 2 | 2010-11-01 | 2016-09-09 |
NCT02503709 | Metastatic Malignant Solid Neoplasm|Unresectable Solid Neoplasm | Drug: CDKI AT7519|Other: Laboratory Biomarker Analysis|Drug: Onalespib|Other: Pharmacological Study | National Cancer Institute (NCI) | Phase 1 | 2016-04-01 | 2017-03-10 |
NCT00390117 | Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific | Drug: CDKI AT7519|Other: laboratory biomarker analysis | NCIC Clinical Trials Group|Canadian Cancer Trials Group | Phase 1 | 2006-08-01 | 2016-11-25 |
NCT01652144 | Mantle Cell Lymphoma | Drug: AT7519M | NCIC Clinical Trials Group|Astex Pharmaceuticals|Canadian Cancer Trials Group | Phase 2 | 2012-08-01 | 2016-10-25 |
NCT01627054 | Chronic Lymphocytic Leukemia | Drug: AT7519M | NCIC Clinical Trials Group|Astex Pharmaceuticals|Canadian Cancer Trials Group | Phase 2 | 2012-08-01 | 2016-10-25 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们